- Home
- PODC vs VYNE Comparison
PODC vs VYNE Comparison
Compare PODC & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- VYNE
- Stock Information
- Founded
- PODC 2013
- VYNE 2003
- Country
- PODC United States
- VYNE United States
- Employees
- PODC N/A
- VYNE N/A
- Industry
- PODC
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- PODC
- VYNE Health Care
- Exchange
- PODC Nasdaq
- VYNE Nasdaq
- Market Cap
- PODC 44.2M
- VYNE 38.2M
- IPO Year
- PODC N/A
- VYNE 2018
- Fundamental
- Price
- PODC $1.54
- VYNE $1.90
- Analyst Decision
- PODC Strong Buy
- VYNE Strong Buy
- Analyst Count
- PODC 2
- VYNE 1
- Target Price
- PODC $4.75
- VYNE $5.75
- AVG Volume (30 Days)
- PODC 17.4K
- VYNE 40.5K
- Earning Date
- PODC 08-13-2024
- VYNE 08-14-2024
- Dividend Yield
- PODC N/A
- VYNE N/A
- EPS Growth
- PODC N/A
- VYNE N/A
- EPS
- PODC N/A
- VYNE N/A
- Revenue
- PODC $45,824,000.00
- VYNE $486,000.00
- Revenue This Year
- PODC $33.16
- VYNE $32.31
- Revenue Next Year
- PODC $20.37
- VYNE N/A
- P/E Ratio
- PODC N/A
- VYNE N/A
- Revenue Growth
- PODC 25.32
- VYNE 19.41
- 52 Week Low
- PODC $1.20
- VYNE $1.57
- 52 Week High
- PODC $4.00
- VYNE $4.48
- Technical
- Relative Strength Index (RSI)
- PODC 54.11
- VYNE 53.49
- Support Level
- PODC $1.47
- VYNE $1.77
- Resistance Level
- PODC $1.73
- VYNE $1.98
- Average True Range (ATR)
- PODC 0.06
- VYNE 0.10
- MACD
- PODC 0.02
- VYNE 0.02
- Stochastic Oscillator
- PODC 51.16
- VYNE 51.61
About PODC PodcastOne Inc.
PodcastOne Inc Formerly CourtSide Group Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.